Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial.

Nat Commun · 2025 · PMC11961741 · PMID 40169605

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Notably, PD-1 expression was significantly upregulated in tumors after neoadjuvant Aumolertinib treatment compared to baseline, with an increasing trend in PD-L1 expression (Fig. 4f ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.